SCYNEXIS, Inc.
SCYX
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasiā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.07
Price+4.75%
$0.23
1Y
Price
Market Cap
$31.884m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$20.344m
-1.2%
1y CAGR+117.1%
3y CAGR+751.0%
5y CAGREarnings
-$24.517m
-184.8%
1y CAGR-85.7%
3y CAGR-12.6%
5y CAGREPS
-$3.58
-163.2%
1y CAGR-77.8%
3y CAGR-9.7%
5y CAGRBook Value
$41.307m
$77.626m
Assets$36.319m
Liabilities$2.061m
DebtDebt to Assets
2.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$5.919m
-12.0%
1y CAGR-24.6%
3y CAGR+25.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company